Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
GARDEN CITY, N.Y., and REHOVOT, Israel, March 13, 2019 (GLOBE NEWSWIRE) -- AIT Therapeutics, Inc. (OTCQB: AITB), a clinical-stage medical device and biopharmaceutical company focused on developing...
-
Announced transformational partnership agreement with Circassia Pharmaceuticals PMA filing for treatment of PPHN on track for second quarter calendar 2019 Completed treatment safely of a...
-
GARDEN CITY, N.Y. and REHOVOT, Israel, Feb. 11, 2019 (GLOBE NEWSWIRE) -- AIT Therapeutics, Inc. (OTCQB: AITB), a clinical-stage medical device and biopharmaceutical company focused on developing...
-
NEW YORK, Feb. 05, 2019 (GLOBE NEWSWIRE) -- AIT Therapeutics, Inc. (OTCQB: AITB), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for...
-
Milestone payment triggered by successful completion of a pre-submission meeting with the FDA AIT has received $10.5 million to date in upfront and milestone payments PMA submission on track for...
-
Additionally, AIT to garner a 15%-20% royalty on gross profit AIT will immediately request to be listed on the NASDAQ stock exchange PMA submission on track for the second quarter of 2019 Company...
-
GARDEN CITY, N.Y. and REHOVOT, Israel, Jan. 02, 2019 (GLOBE NEWSWIRE) -- AIT Therapeutics, Inc. (OTCQB: AITB), a clinical-stage medical device and biopharmaceutical company focused on developing...
-
AIT to receive up to $32.5 million in up-front and regulatory milestones Additionally, AIT to receive a 15%-20% royalty on annual gross profit Partner to receive rights to all indications at nitric...
-
PMA filing for treatment of PPHN expected in calendar second quarter 2019 Pivotal Bronchiolitis trial to initiate in calendar fourth quarter 2019 in the US Positive clinical and pre-clinical data...
-
GARDEN CITY, N.Y. and REHOVOT, Israel, Nov. 05, 2018 (GLOBE NEWSWIRE) -- AIT Therapeutics, Inc. (OTCQB: AITB), a clinical-stage medical device and biopharmaceutical company focused on developing...